Gelonghui, April 18, 丨 Le Méridien Vaccine (06660.HK) announced that the company's board of directors received a notice from Zhou Yan (Chairman of the Board, Executive Director, CEO and controlling shareholder of the company). Zhou Yan continued to further increase the company's H shares through the open market from January 22, 2024 to April 18, 2024. From November 14, 2023 to April 18, 2024, Zhou Yan has continued to increase her H shares in the company through the open market with total capital of HK$10,420,212.00, and it is not ruled out that she will continue to increase her shares in due course.
As of the date of this announcement, the company's operations, finance, and sales of existing products were normal, and vaccine research and development in the research pipeline progressed normally according to the plan. The board of directors believes that Zhou Yan's continuous increase in the company's shares with his own capital is a judgment based on the company's intrinsic value and future growth potential. It shows his confidence and recognition of the company's future development, and is conducive to the implementation of the company's long-term strategic layout.
After this increase in holdings and on the date of this announcement, the company still met the requirements for sufficient public shareholding as stipulated in section 8.08 of the Listing Rules. This increase in holdings did not trigger mandatory offer obligations under the “Code of Corporate Takeovers and Mergers”. This increase in holdings also did not result in a change in the company's control.
Shareholders and potential investors are advised to exercise caution when trading the company's securities.